Project Grant K38CA292995
Award Date
8/1/24
Completion Date
7/31/26
Dollars Obligated
$201K
Federal Agency
National Cancer Institute
Awardee
Duke University (TP7EK8DZV6N5)
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Durham, NC 27710, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $954,000 Project Grant (CFDA 93.396 - Cancer Biology Research) to the University of Pittsburgh to investigate how aging promotes the growth of glioblastoma, one of the most lethal forms of cancer. The research aims to leverage insights from the biology of neural stem cells and the molecular circuitry of cancer stem cells to understand how aging creates a tumor microenvironment that supports the survival and proliferation of glioblastoma. The...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $609,749 to the University of North Carolina at Chapel Hill to develop a novel combination therapy for the treatment of glioblastoma multiforme (GBM), the most aggressive form of brain cancer. The key products/services to be delivered include: Developing an injectable, biodegradable hydrogel scaffold that can accommodate high concentrations of induced neural stem cells...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $552,968 to the University of Pittsburgh to conduct research on the role of tRNA modifications in glioblastoma stem cell maintenance and translational reprogramming. The research aims to understand how metabolic regulation of tRNA modification enzymes and amino acid availability impacts tRNA landscapes and codon-biased translation in glioblastoma, a highly lethal form of brain cancer....
The National Cancer Institute (NCI) awarded a $730,398 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sloan-Kettering Institute for Cancer Research. The grant supports a 5-year research project investigating the relationship between inflammatory signaling in the leptomeninges (the membranes surrounding the brain and spinal cord) and the growth of leptomeningeal metastases, which are a lethal complication of cancer. The project leverages the institute's collection of...
The National Cancer Institute (NCI) awarded a $678,228 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop GLISCAN - a multi-analyte, multi-mutation blood-based assay for rapid, sensitive molecular subtyping of gliomas. The three-phase study will optimize, verify, and validate the GLISCAN assay, which aims to quantify tumor mutations (TERT C228T/C250T,...
The National Cancer Institute (NCI) awarded a $417,586 Project Grant (CFDA 93.396 - Cancer Biology Research) to The Broad Institute, Inc. to develop a "Platform for Multi-Modal Single Nucleus Spatial Genomics for Molecular Tumor Analysis." This 3-year project, commencing on August 1, 2024, aims to extend the institute's "Slide-Tags" single-cell spatial genomics technology to enable comprehensive profiling of human tumor samples. The project will integrate molecular, cellular,...
The National Cancer Institute (NCI) awarded a $1,064,642 Project Grant (CFDA 93.396 - Cancer Biology Research) to Tufts Medical Center Parent, Inc. (doing business as Tufts Medical Center) to characterize the role of the angiogenin (ANG) and plexin-B2 (PLXNB2) signaling axis in regulating glioma stem cell (GSC) properties and glioblastoma (GBM) recurrence. The research aims to elucidate the mechanism by which the ANG-PLXNB2-tRNA-derived small RNA (TRNA) pathway maintains GSC stemness and...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $417,858 to Brigham & Women's Hospital Inc. to develop a novel cellular therapy platform for the treatment of glioblastoma, a highly malignant brain cancer. The project aims to engineer mesenchymal stem cells (MSCs) to release bi-specific T-cell engager (BiTE) molecules targeting multiple tumor antigens (EGFR, EGFRvIII, IL13RA2) and co-express IL-12 and immune checkpoint inhibitors....
This Project Grant award, identified as K99CA297018, was provided by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) federal grant program. The $170,655 award, with a period of performance from July 1, 2025 to June 30, 2027, supports research focused on "Mapping Intercellular Protein Trafficking in Glioblastoma with Esterase-Activated Proximity Labeling". The primary goals of this project are to develop a new molecular method for mapping protein...
This $732,000 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will support research under the Cancer Treatment Research program. The grant recipient, Northwestern University, will develop a bridge-lipid nanoparticle platform to reprogram immunosuppressive tumor-associated myeloid cells and potentiate radiotherapy for glioblastoma. Over a five-year period, the university will conduct three aims: harnessing myeloid cells to phagocytose...